Financial Ratios IDEXX Laboratories, Inc.
Stocks
IDXX
US45168D1046
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 566.23 USD | +1.67% |
|
-0.22% | -16.71% |
| 05-27 | IDEXX Laboratories, Inc. Presents at Stifel Jaws & Paws Conference 2026, May-27-2026 10:55 AM | |
| 05-26 | IDEXX Laboratories Expands Fecal Antigen Testing Platform With Tapeworm Detection | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 24.62 | 21.67 | 22.83 | 22.7 | 25.59 | |||||
Return on Total Capital | 34.7 | 29.57 | 29.62 | 28.97 | 32.92 | |||||
Return On Equity % | 112.62 | 104.58 | 80.74 | 57.66 | 66.2 | |||||
Return on Common Equity | 112.68 | 104.58 | 80.74 | 57.66 | 66.2 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 58.76 | 59.52 | 59.82 | 61.04 | 61.8 | |||||
SG&A Margin | 24.77 | 25.26 | 24.64 | 24.87 | 24.36 | |||||
EBITDA Margin % | 32.24 | 30.01 | 33.11 | 33.86 | 34.97 | |||||
EBITA Margin % | 29.36 | 27.14 | 30.35 | 30.97 | 32.07 | |||||
EBIT Margin % | 28.99 | 26.69 | 29.97 | 30.53 | 31.6 | |||||
Income From Continuing Operations Margin % | 23.17 | 20.17 | 23.08 | 22.78 | 24.62 | |||||
Net Income Margin % | 23.17 | 20.17 | 23.08 | 22.78 | 24.62 | |||||
Net Avail. For Common Margin % | 23.17 | 20.17 | 23.08 | 22.78 | 24.62 | |||||
Normalized Net Income Margin | 17.55 | 15.96 | 18.12 | 18.78 | 19.23 | |||||
Levered Free Cash Flow Margin | 16.62 | 9.75 | 18.95 | 18.86 | 18.37 | |||||
Unlevered Free Cash Flow Margin | 17.2 | 10.49 | 19.66 | 19.36 | 18.94 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 1.36 | 1.3 | 1.22 | 1.19 | 1.3 | |||||
Fixed Assets Turnover | 4.8 | 4.61 | 4.62 | 4.73 | 5.06 | |||||
Receivables Turnover (Average Receivables) | 8.45 | 7.94 | 7.67 | 7.45 | 7.4 | |||||
Inventory Turnover (Average Inventory) | 5.54 | 4.28 | 3.93 | 3.98 | 4.33 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.25 | 0.89 | 1.57 | 1.31 | 1.23 | |||||
Quick Ratio | 0.75 | 0.49 | 1.03 | 0.8 | 0.76 | |||||
Operating Cash Flow to Current Liabilities | 0.99 | 0.44 | 0.95 | 0.87 | 1.03 | |||||
Days Sales Outstanding (Average Receivables) | 43.22 | 45.99 | 47.61 | 49.15 | 49.3 | |||||
Days Outstanding Inventory (Average Inventory) | 65.92 | 85.27 | 92.81 | 91.85 | 84.32 | |||||
Average Days Payable Outstanding | 25.13 | 28.26 | 27.17 | 27.07 | 25 | |||||
Cash Conversion Cycle (Average Days) | 84 | 103 | 113.25 | 113.93 | 108.62 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 149.43 | 241.49 | 71.9 | 61.87 | 60.83 | |||||
Total Debt / Total Capital | 59.91 | 70.72 | 41.83 | 38.22 | 37.82 | |||||
LT Debt/Equity | 125.02 | 130.7 | 48.67 | 34.33 | 29.68 | |||||
Long-Term Debt / Total Capital | 50.12 | 38.27 | 28.31 | 21.21 | 18.45 | |||||
Total Liabilities / Total Assets | 71.69 | 77.84 | 54.46 | 51.56 | 52.09 | |||||
EBIT / Interest Expense | 31.27 | 22.55 | 26.39 | 38.13 | 35.01 | |||||
EBITDA / Interest Expense | 35.63 | 26.08 | 29.91 | 43.38 | 39.73 | |||||
(EBITDA - Capex) / Interest Expense | 31.62 | 22.34 | 26.7 | 39.51 | 36.52 | |||||
Total Debt / EBITDA | 0.97 | 1.41 | 0.86 | 0.73 | 0.63 | |||||
Net Debt / EBITDA | 0.83 | 1.31 | 0.49 | 0.52 | 0.52 | |||||
Total Debt / (EBITDA - Capex) | 1.09 | 1.65 | 0.96 | 0.8 | 0.69 | |||||
Net Debt / (EBITDA - Capex) | 0.94 | 1.52 | 0.55 | 0.57 | 0.56 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 18.79 | 4.73 | 8.72 | 6.46 | 10.42 | |||||
Gross Profit, 1 Yr. Growth % | 20.27 | 6.08 | 9.26 | 8.63 | 11.8 | |||||
EBITDA, 1 Yr. Growth % | 31.13 | -2.5 | 19.92 | 8.89 | 14.05 | |||||
EBITA, 1 Yr. Growth % | 34.05 | -3.22 | 21.58 | 8.64 | 14.36 | |||||
EBIT, 1 Yr. Growth % | 34.2 | -3.57 | 22.07 | 8.45 | 14.3 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 27.95 | -8.83 | 24.44 | 5.07 | 19.33 | |||||
Net Income, 1 Yr. Growth % | 28.03 | -8.83 | 24.44 | 5.07 | 19.33 | |||||
Normalized Net Income, 1 Yr. Growth % | 36.47 | -4.73 | 23.4 | 10.38 | 13.05 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 28.17 | -6.63 | 25.28 | 6.06 | 22.59 | |||||
Accounts Receivable, 1 Yr. Growth % | 14.31 | 8.95 | 15.84 | 4.25 | 17.57 | |||||
Inventory, 1 Yr. Growth % | 28.19 | 36.72 | 3.39 | 0.42 | -1.08 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 7.18 | 10.87 | 6.46 | 1.42 | 4.99 | |||||
Total Assets, 1 Yr. Growth % | 6.22 | 12.7 | 18.68 | 1.03 | 1.74 | |||||
Tangible Book Value, 1 Yr. Growth % | -31.11 | -35.55 | 592.75 | 4.3 | 0.28 | |||||
Common Equity, 1 Yr. Growth % | 9.16 | -11.78 | 143.87 | 7.46 | 0.63 | |||||
Cash From Operations, 1 Yr. Growth % | 16.59 | -28.13 | 66.95 | 2.48 | 27.21 | |||||
Capital Expenditures, 1 Yr. Growth % | 11.77 | 24.5 | -10.22 | -9.51 | 3.1 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 22.37 | -38.59 | 111.39 | 5.95 | 7.58 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 20.91 | -36.16 | 103.83 | 4.84 | 8.02 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 15.58 | 11.54 | 6.7 | 7.58 | 8.42 | |||||
Gross Profit, 2 Yr. CAGR % | 17.63 | 12.95 | 7.66 | 8.94 | 10.2 | |||||
EBITDA, 2 Yr. CAGR % | 26.12 | 13.07 | 8.13 | 14.27 | 11.44 | |||||
EBITA, 2 Yr. CAGR % | 28.35 | 13.9 | 8.47 | 14.93 | 11.46 | |||||
EBIT, 2 Yr. CAGR % | 28.58 | 13.76 | 8.5 | 15.06 | 11.34 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 31.95 | 8.01 | 6.51 | 14.34 | 11.97 | |||||
Net Income, 2 Yr. CAGR % | 31.96 | 8.04 | 6.51 | 14.34 | 11.97 | |||||
Normalized Net Income, 2 Yr. CAGR % | 30.14 | 14.03 | 8.43 | 16.71 | 11.71 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 32.62 | 9.39 | 8.16 | 15.27 | 14.03 | |||||
Accounts Receivable, 2 Yr. CAGR % | 18.96 | 11.6 | 12.34 | 9.89 | 10.71 | |||||
Inventory, 2 Yr. CAGR % | 17.45 | 32.39 | 18.89 | 1.89 | -0.33 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 6.18 | 9.01 | 8.64 | 3.9 | 3.19 | |||||
Total Assets, 2 Yr. CAGR % | 15.33 | 9.41 | 15.65 | 9.5 | 1.38 | |||||
Tangible Book Value, 2 Yr. CAGR % | 38.51 | -33.37 | 111.3 | 168.8 | 2.27 | |||||
Common Equity, 2 Yr. CAGR % | 97.18 | -1.86 | 46.68 | 61.89 | 3.99 | |||||
Cash From Operations, 2 Yr. CAGR % | 28.28 | -8.47 | 9.54 | 30.8 | 14.18 | |||||
Capital Expenditures, 2 Yr. CAGR % | -12.17 | 17.96 | 5.73 | -9.86 | -3.41 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 34.4 | -13.34 | 13.93 | 49.66 | 6.77 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 32.45 | -12.17 | 14.08 | 46.18 | 6.42 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 13.26 | 11.84 | 10.59 | 6.62 | 8.52 | |||||
Gross Profit, 3 Yr. CAGR % | 15.02 | 13.65 | 11.71 | 7.98 | 9.89 | |||||
EBITDA, 3 Yr. CAGR % | 21.74 | 15.75 | 15.31 | 8.38 | 14.2 | |||||
EBITA, 3 Yr. CAGR % | 23.58 | 16.82 | 16.4 | 8.53 | 14.74 | |||||
EBIT, 3 Yr. CAGR % | 23.79 | 16.82 | 16.46 | 8.48 | 14.81 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 25.47 | 16.65 | 13.23 | 6.03 | 15.98 | |||||
Net Income, 3 Yr. CAGR % | 25.48 | 16.66 | 13.25 | 6.03 | 15.98 | |||||
Normalized Net Income, 3 Yr. CAGR % | 25.4 | 17.29 | 17.07 | 9.07 | 15.48 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 26.39 | 17.98 | 14.45 | 7.45 | 17.66 | |||||
Accounts Receivable, 3 Yr. CAGR % | 16.25 | 15.53 | 13 | 9.58 | 12.39 | |||||
Inventory, 3 Yr. CAGR % | 15.79 | 23.55 | 21.91 | 12.38 | 0.89 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 16.58 | 7.72 | 8.15 | 6.18 | 4.26 | |||||
Total Assets, 3 Yr. CAGR % | 16.6 | 14.44 | 12.42 | 10.56 | 6.85 | |||||
Tangible Book Value, 3 Yr. CAGR % | -4.49 | 7.33 | 45.43 | 66.99 | 93.5 | |||||
Common Equity, 3 Yr. CAGR % | 317.04 | 50.81 | 32.92 | 32.23 | 38.16 | |||||
Cash From Operations, 3 Yr. CAGR % | 23.61 | 5.75 | 11.84 | 7.13 | 29.59 | |||||
Capital Expenditures, 3 Yr. CAGR % | 1.08 | -1.34 | 7.7 | 0.38 | -5.73 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 26.76 | 3.52 | 16.66 | 11.21 | 34.06 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 24.86 | 3.85 | 16.29 | 10.91 | 32.16 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 12.61 | 11.33 | 10.59 | 10.12 | 9.72 | |||||
Gross Profit, 5 Yr. CAGR % | 14.14 | 12.8 | 12.02 | 11.74 | 11.1 | |||||
EBITDA, 5 Yr. CAGR % | 19.2 | 15.29 | 16.1 | 15.16 | 13.75 | |||||
EBITA, 5 Yr. CAGR % | 21.14 | 16.71 | 17.3 | 16.06 | 14.4 | |||||
EBIT, 5 Yr. CAGR % | 21.47 | 16.82 | 17.43 | 16.11 | 14.39 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 27.39 | 20.87 | 17.52 | 15.72 | 12.72 | |||||
Net Income, 5 Yr. CAGR % | 27.39 | 20.88 | 17.52 | 15.73 | 12.74 | |||||
Normalized Net Income, 5 Yr. CAGR % | 22.74 | 17.69 | 18.31 | 17.06 | 14.89 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 28.65 | 22.26 | 18.75 | 16.89 | 14.28 | |||||
Accounts Receivable, 5 Yr. CAGR % | 14.71 | 13.53 | 14.67 | 13.24 | 12.08 | |||||
Inventory, 5 Yr. CAGR % | 11.23 | 17.49 | 17.02 | 14.39 | 12.47 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 14.15 | 15.17 | 13.34 | 6.18 | 6.14 | |||||
Total Assets, 5 Yr. CAGR % | 9.75 | 9.9 | 16.22 | 12.44 | 7.87 | |||||
Tangible Book Value, 5 Yr. CAGR % | -6.99 | -12.9 | 31.22 | 54.96 | 26.32 | |||||
Common Equity, 5 Yr. CAGR % | 44.81 | 62.27 | 174.57 | 55.15 | 20.49 | |||||
Cash From Operations, 5 Yr. CAGR % | 17.39 | 7.78 | 17.77 | 15.14 | 12.77 | |||||
Capital Expenditures, 5 Yr. CAGR % | 13.03 | 14.88 | 2.91 | -4.84 | 3.11 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 12.34 | 6.06 | 21.46 | 19.96 | 12.6 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 11.65 | 5.69 | 20.43 | 19.07 | 12.23 |
- Stock Market
- Stocks
- IDXX Stock
- Financials IDEXX Laboratories, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















